TriangleIvonescimab (NCT07229417)
Ivonescimab trial for Metastatic Endocrine Refractory (NCT07229417). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic, HER2-negative invasive lobular breast cancer and negative E-cadherin staining. Hormone-receptor-positive disease must resist endocrine therapy after at least one such treatment; triple-negative disease also qualifies. At most two metastatic chemotherapy or antibody-drug-conjugate agents are allowed.
The idea: ivonescimab targets PD-1 immune suppression and VEGF blood-vessel signaling. Infusions repeat every three weeks. Researchers assess disease control and safety. Biopsy is required when the tumor is safely accessible.
This phase 2 study plans 29 patients. Jason Mouabbi leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.